Safety and immunogenicity of bk-se36 in a blinded, randomized, controlled, age de-escalating phase ib clinical trial in burkinabe children

HIGHLIGHTS

• who: Edith Christiane Bougouma from the RenéRachou Institute (FIOCRUZ), Brazil Diseases, Osaka University, Suita have published the article: Safety and immunogenicity of BK-SE36 in a blinded, randomized, controlled, age de-escalating phase Ib clinical trial in Burkinabe children, in the Journal: (JOURNAL) of January/11,/2016
• what: The encouraging results from the phase I trial in Uganda justified the conduct of a trial in younger cohorts, which the authors report here. The aim of the study was to assess the safety and reactogenicity of 3 full doses of BK-SE36 (100 µg SE36 . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.